Clinical trial · Observational
Netrin-1 & Hepatocellular Carcinoma HCC
Netrin-1 in Hepatocellular Carcinoma: Pathology, Preclinical Targeting, and Definition of Eligibility Criteria for Phase 1 Trials
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Netrin-1 is a dependence receptor ligand participating in the pathology of several cancer types. It is up-regulated in chronic liver diseases, cirrhosis and HCC. We hypothesize that netrin-1 may play a detrimental role in HCC. The goal of this project is to characterize netrin-1 signals in HCC samples with ad hoc controls, to investigate the benefit of capturing netrin-1 in preclinical models of HCC and to try to define patients groups the most likely to benefit from this targeting approach in the clinic.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| HCC | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Quantification of netrin-1 signals by antibody-based approaches | Procedure | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- label
- Tumors (T) samples of various etiologies (HBV, HCV, NASH, alcool)
- description
- The combination of the Tumors status of the sample combined with its etiology ((HBV, HCV, NASH, alcool)
- interventionNames
- Procedure: Quantification of netrin-1 signals by antibody-based approaches
- label
- Non Tumors (NT) samples of various etiologies (HBV, HCV, NASH, alcool)
- description
- The combination of the Non Tumors status of the sample combined with its etiology ((HBV, HCV, NASH, alcool)
- interventionNames
- Procedure: Quantification of netrin-1 signals by antibody-based approaches
Primary outcomes (1)
- measure
- Netrin-1 expression patterns in HCC samples
- timeFrame
- Outcome measure is to be performed after surgery of the tumors (at least 1 year later). It has no impact on the patient's care.
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 85 Years
Show eligibility criteria text
Inclusion Criteria: * any patient suffering from HCC * age \>18 * informed consent provided Exclusion Criteria: \- absence of informed consent
References
Publications (0)
Data not yet available